File:RcAAV Testing.png

While AAV vectors are engineered to be replication defective, generation of replication-competent AAV (rcAAV) can still occur during vector manufacturing by means of recombination events within the producer cells. rcAAV may develop at any step during the manufacturing process of gene therapy products. Even though vector production systems have been specifically developed to reduce the risk of rcAAV generation, there is still a significant safety concern driving the recommendations for testing for rcAAV in cell banks, vector and final product release for AAV-based gene therapy products. https://www.creative-biogene.com/Services/Custom-Viral-Service/Replication-Competent-AAV-Testing.html